Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

1.840 -0.030 (-1.60%)
Streaming Delayed Price Updated: 11:25 AM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. 
Via InvestorPlace
Immuneering Announces Participation in February Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
4 Analysts Have This to Say About Immuneering
Via Benzinga
Expert Ratings for Immuneering
Via Benzinga
Analyst Doubles Immuneering Price Target Citing Initial Data Validation
Via Benzinga
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
What 7 Analyst Ratings Have To Say About Immuneering
Via Benzinga
Why Shares of Immuneering Jumped This Week
Immuneering is ready to share information regarding its lead therapy. 
Via The Motley Fool
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Morgan Stanley Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Jefferies Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces $30 Million Underwritten Offering
From Immuneering Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
Via Benzinga
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - 
From Immuneering Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise 
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS